Estrogen and progesterone receptors in ovarian cancer

Harding, M.; Cowan, Sheila K.; Hole, D.; Cassidy, Lauren; Kitchener, Henry C; Davis, Jo Ann; Leake, R E

doi:10.1002/1097-0142(19900201)65:3<486::aid-cncr2820650319>3.0.co;2-c

Cited by 63 publications

(33 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Whereas there is some evidence that ER expression does not play a prognostic role in ovarian cancer (Harding et al, 1990;Rose et al, 1990;Sevelda et al, 1990;Slotman et al, 1990), there is no agreement as to PR expression. Although some authors have reported that PR expression is a favourable prognostic factor (Harding et al, 1990;Sevelda et al, 1990;Slotman et al, 1990;van der Burg et al, 1993), we were not able to confirm this finding, in agreement with Rose et al (1990).…”

Section: Resultscontrasting

confidence: 91%

“…Although some authors have reported that PR expression is a favourable prognostic factor (Harding et al, 1990;Sevelda et al, 1990;Slotman et al, 1990;van der Burg et al, 1993), we were not able to confirm this finding, in agreement with Rose et al (1990). Although the discrepancies may be due to different cut-off values and patient populations, it may be that PR positivity has only a minor prognostic impact since steroid hormones play a marginal role in onset and spread of ovarian cancer.…”

Section: Resultsmentioning

confidence: 99%

“…Data on the role of the expression of oestrogen receptor (ER) and progesterone receptor (PR) in ovarian cancer are discordant, although many authors have demonstrated that positivity for steroid hormone receptors is associated with a better prognosis (Harding et al, 1990;Rose et al, 1990;Sevelda et al, 1990;Slotman et al, 1990). In this report the prognostic significance of EGFR, ER and PR was simultaneously analysed in a large prospective series of primary ovarian cancer patients observed for a long follow-up period.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy

Scambia

Benedetti‐Panici²,

Ferrandina³

et al. 1995

Br J Cancer

View full text Add to dashboard Cite

Summary The expression of epidermal growth factor receptor (EGFR), oestrogen receptor (ER) and progesterone receptor (PR) was assayed by a radioreceptor method in 117 primary ovarian cancers. EGFR was not significantly related to any of the clinicopathological parameters examined. In patients with stage II-IV disease who underwent second-look surgery after primary chemotherapy, a significant correlation between high EGFR levels and poor response to chemotherapy was demonstrated (P = 0.031). Moreover, post-operative residual tumour showed an independent role in predicting chemotherapy response (P = 0.0007) and EGFR status showed a borderline significance (P = 0.052) in the multivariate analysis. No correlation between steroid hormone receptors and clinicopathological parameters was observed. Whereas a significant relationship was shown between EGFR positivity and a shorter overall survival (OS) (P = 0.0022) and progression-free survival (PFS) (P = Neal et al., 1991;Maurizi et al., 1992; Scambia et al., 1994). Moreover, in breast cancer EGFR expression seems to be a feature of hormone-independent aggressive clinical behaviour (Klijn et al., 1992). Our previous study The membrane fraction and cytosol were prepared as described elsewhere . Briefly, tumour specimens were finely minced and homogenised in five volumes of ice-cold buffer consisting of 25 mM Tris, 1.5 mM EDTA, 5 mM sodium azide, 20% glycerol (TENG) plus 0.1 % monothioglycerol, by applying several intermittent bursts of an Ultra-Turrax homogeniser. The crude homogenate was centrifuged at 7000 g for 20 min at 0°C in order to separate nuclear fraction from the cytosol fraction. The supernatants were then centrifuged at 105 000 g for 75 min at 0°C, obtaining the membrane pellet and the cytosolic fraction.

show abstract

Section: Resultscontrasting

confidence: 91%

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy

Scambia

Benedetti‐Panici²,

Ferrandina³

et al. 1995

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…These lower E 2 levels may account for the lower ovarian cancer rates in Asian women. Although estrogen receptor (ER) positivity is found in 50-70% of ovarian cancers (22), whether E 2 enhances OEC development through ER signaling is still not clear. In breast carcinogenesis, some studies indicate that induction of ER-mediated signaling is not sufficient for the development of breast cancer and the underlying mechanisms of breast susceptibility to estrogen's carcinogenic effect may correlate with ROS induced by E 2 (23).…”

Section: Nrf2 Expression --------------------------------------------mentioning

confidence: 99%

NRF2 is overexpressed in ovarian epithelial carcinoma and is regulated by gonadotrophin and sex-steroid hormones

et al. 2012

View full text Add to dashboard Cite

Abstract. Aberrant nuclear factor-erythroid 2 (NRF2) expression correlates with tumor development. We investigated NRF2 expression in ovarian epithelial carcinoma (OEC), aiming to identify associations with clinicopathological factors, hormones and induced reactive oxygen species (ROS). Immunohistochemical staining for NRF2 expression was performed on 10 benign cystadenomas, 4 boderline tumors and 64 OECs. Western blotting was used to determine the effects of hormones on NRF2 expression in OEC. NRF2 protein was found to be overexpressed in OEC. Gonadotrophins and estrogen induced ROS production in OEC; these hormones also enhanced NRF2 expression. Therefore, aberrant expression may be induced by hormones through ROS signaling. Increased NRF2 expression may be a molecular event in OEC carcinogenesis.

show abstract

“…Various receptors which are over-expressed at tumor cells are epidermal growth factor receptor (EGFR) (Torp et al, 1991;Rusch et al, 1996), folate receptor (FRs) (Weitman et al, 1992), transferrin receptor (TRs) (Recht et al, 1990), fucose receptor Seymour, 1994), estrogen receptors (ERs) (Harding et al, 1990;Loven et al, 1990), and androgen receptor (ARs) (Kampa et al, 2002;Das et al, 2006), etc. These ligands have been proposed for site-specific delivery of different imaging agents or therapeutic agents via conjugated drug delivery.…”

Section: Introductionmentioning

confidence: 96%